Skip to content
Search

Latest Stories

Indian-Origin Banker Among Three Held In London Over $2 Billion Fraud

An Indian-origin banker, Surjan Singh, 44 is one among the three arrested in London on Thursday (4) and face extradition to the US following alleged role in a $2 billion fraud schemes associated with the firms in Mozambique.

Singh was arrested along with Andrew Pearse, 49 and Detelina Subeva, 37, and charged in an indictment issued by a US district court in New York, according to the US authorities.


All the three accused are the former Credit Suisse bankers, have been released on bail and are facing extradition to the US on the charges. According to the media reports, the scheme involved loans to state-owned firms in Mozambique.

According to the US indictment, through a series of financial transactions during 2013 and 2016, a sum of more than $2bn was borrowed through loans guaranteed by the Mozambican government.

Over the course of the financial transactions, the co-conspirators acted to defraud investors.

The accused created maritime projects as fronts to raise money to enrich themselves, and "intentionally diverted portions of the loan proceeds to pay at least $200 million in bribes and kickbacks to themselves, Mozambican government officials and others," the indictment reads.

Swiss lender Credit Suisse said its three former staff were accused by the US government of "circumventing our internal controls" in a fraud case linked to the Mozambican government.

"No action has been taken against Credit Suisse. The indictment alleges that the former employees worked to defeat the bank's internal controls, acted out of a motive of personal profit, and sought to hide these activities from the bank," the lender said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less